Alpha Cognition Inc. announced that its partner, China Medical System Holdings Limited (CMS), has had its New Drug Application (NDA) for ZUNVEYL accepted by the National Medical Products Administration (NMPA) of China for review. The application is for the treatment of mild-to-moderate Alzheimer’s dementia.
This acceptance marks a significant regulatory milestone, advancing ZUNVEYL towards potential commercialization in the Asia market. China has an estimated 7.93 million patients with mild-to-moderate Alzheimer dementia, representing a substantial market opportunity.
Alpha Cognition is eligible to receive regulatory and sales milestones, as well as royalties, should ZUNVEYL be approved for marketing in China and other Asian territories. The company will rely on CMS's expertise for regulatory and commercial success in the Chinese market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.